摘要
目的：比较经肝动脉插管仅灌注化疗药物和插管灌注化疗药物后再栓塞两种介入方法治疗原发性肝癌的生存率情况。方法；通过CBMdisc数据库检索1980－1999年发表的研究报告，复习检出文章的参考文献，确定有上述两种方法、临床观察时间至少1年的相关研究进行Meta分析。在检出的研究报告中有19篇符合入选标准。按标准提取来源地区、样本数量、研究时间、治疗方案及生存率情况。结果：通过定量分析比较，化疗栓塞组的1、2、3年生存率均高于灌注化疗组。19篇研究对照研究的1年权重生存率差及其95％的可信限为30．42％（27．49％，33．35％），14篇研究的2年权重平均率差为7．38％（6．00％，8．76％），8篇研究的3年权重平均率差为1．78％（8．87％，12．69％），各年率差均有统计学差异（P＜0．05）。结论：经肝动脉插管灌注化疗药物后再栓塞可以明显提高患者的生存率。
Purpose: To compare the intervention therapeutic efficacy with transcatheter oily chemoem-bolization and only transcatheter for patients with primary liver cancer(PLC). Methods: We identified Chinese-language studies published between 1980 to 1999 by searching the CBMdisc databases and reviewing the bibliographies of identified articles to locate additional relevant studies. Clinical studies comparing the two intervention ways lasting at least 1 year were reviewed. Nineteen identified studies met the inclusion criteria. Information on region of origin, sample size, duration, therapeutic formula, and survival rate was abstracted independently by 2 authors who used a standardized protocol. Results: This quantitative review shows that the survival rate of patients treated by transcatheter oily chemoembolization is higher than those treated only by transcatheter in every year. The survival rate diversity indicate that 19 clinical contrast studies of one-year is 30.42% (95% confidence interval CI, 27. 49% -33. 35% , P <0. 01), 14 clinical contrast studies of two-year is 7.38% (95% CI, 6.00%-8.76%, P<0.05), and 8 clinical contrast studies of three-year is 10.78% (95% CI, 8.87%-12.96%,P<0.01). Conclusions: Life-span of .patients with PLC treated by transcatheter oily chemoembolization is remarkably prolonged than those only treated transcatheter.
出处
《临床消化病杂志》
2001年第6期255-259,共5页
Chinese Journal of Clinical Gastroenterology
